Vaxart, Inc. Files 8-K Report
Ticker: VXRT · Form: 8-K · Filed: Aug 6, 2025 · CIK: 72444
| Field | Detail |
|---|---|
| Company | Vaxart, Inc. (VXRT) |
| Form Type | 8-K |
| Filed Date | Aug 6, 2025 |
| Risk Level | low |
| Sentiment | neutral |
Sentiment: neutral
Topics: 8-K, material-agreement, corporate-event
TL;DR
Vaxart filed an 8-K on Aug 5, 2025, reporting a material definitive agreement and other events.
AI Summary
On August 5, 2025, Vaxart, Inc. filed an 8-K report detailing a material definitive agreement and other events. The company, previously known as Aviragen Therapeutics, Inc., Biota Pharmaceuticals, Inc., and NABI BIOPHARMACEUTICALS, is incorporated in Delaware and headquartered in South San Francisco, California.
Why It Matters
This filing provides an update on significant corporate events for Vaxart, Inc., which could impact investors and stakeholders by revealing new material agreements or other important developments.
Risk Assessment
Risk Level: low — This is a routine filing of an 8-K report, which typically discloses material events but does not inherently signal high risk.
Key Numbers
- 001-35285 — SEC File Number (Identifies the company's filing with the SEC)
- 59-1212264 — IRS Employer Identification No. (Tax identification number for the company)
Key Players & Entities
- Vaxart, Inc. (company) — Registrant
- August 5, 2025 (date) — Date of earliest event reported
- Aviragen Therapeutics, Inc. (company) — Former company name
- Biota Pharmaceuticals, Inc. (company) — Former company name
- NABI BIOPHARMACEUTICALS (company) — Former company name
- Delaware (jurisdiction) — State of incorporation
- South San Francisco, California (location) — Address of principal executive offices
FAQ
What specific material definitive agreement was entered into by Vaxart, Inc. on or before August 5, 2025?
The filing indicates an 'Entry into a Material Definitive Agreement' as an item of disclosure, but the specific details of the agreement are not provided in the provided text.
What 'Other Events' are being reported by Vaxart, Inc. in this 8-K filing?
The filing lists 'Other Events' as a category of disclosure, but the specific nature of these events is not detailed in the provided text.
When was Vaxart, Inc. previously known as Aviragen Therapeutics, Inc.?
The date of name change from Aviragen Therapeutics, Inc. to Vaxart, Inc. was April 13, 2016.
What is Vaxart, Inc.'s principal executive office address?
The principal executive offices are located at 170 Harbor Way, Suite 300, South San Francisco, California 94080.
What is the SIC code for Vaxart, Inc.?
The Standard Industrial Classification (SIC) code for Vaxart, Inc. is 2836, which corresponds to BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES).
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on August 6, 2025 regarding Vaxart, Inc. (VXRT).